- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Submit PMS data in Indian Population: CDSCO Panel Tells Sanofi Healthcare on updation prescribing information of Adacel vaccine
![Submit PMS data in Indian Population: CDSCO Panel Tells Sanofi Healthcare on updation prescribing information of Adacel vaccine Submit PMS data in Indian Population: CDSCO Panel Tells Sanofi Healthcare on updation prescribing information of Adacel vaccine](https://medicaldialogues.in/h-upload/2024/01/27/750x450_231047-sanofi-50.webp)
New Delhi: Responding to the proposal presented by Sanofi Healthcare India for updating prescribing information for Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Adacel), the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has opined the firm to submit the data/publication in support of the proposed changes and post-marketing surveillance (PMS) data in the Indian population.
This came after the vaccine maker Sanofi Healthcare India presented its proposal to update prescribing information of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed.
Adacel is a vaccine that helps prevent whooping cough (pertussis), tetanus, and diphtheria. It's manufactured by Sanofi Pasteur Limited and is approved for use in people aged 10-64 who have previously received childhood immunizations. Adacel can also be used during the third trimester of pregnancy to prevent pertussis in infants under 2 months old.
Adacel is a suspension for injection that should be administered into the deltoid muscle. It should not be mixed with other vaccines or drugs, and it should only be used once on one patient. After use, any remaining vaccine should be discarded.
Common side effects of Adacel include headache, injection site redness, pain, swelling, weakness, and gastrointestinal symptoms.
At the recent SEC meeting for vaccines held on August 22, 2024, the expert panel reviewed the revised proposal for an update of prescribing information for Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, or Adacel vaccine.
After detailed deliberation, the committee recommended the firm to submit
1. Data/publications in support of the proposed changes.2. Post marketing surveillance data in Indian Population.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751